- Home
- NTRB vs MRNS Comparison
NTRB vs MRNS Comparison
Compare NTRB & MRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTRB
- MRNS
- Stock Information
- Founded
- NTRB 2016
- MRNS 2003
- Country
- NTRB United States
- MRNS United States
- Employees
- NTRB N/A
- MRNS N/A
- Industry
- NTRB Industrial Specialties
- MRNS Biotechnology: Pharmaceutical Preparations
- Sector
- NTRB Health Care
- MRNS Health Care
- Exchange
- NTRB Nasdaq
- MRNS Nasdaq
- Market Cap
- NTRB 77.9M
- MRNS 104.7M
- IPO Year
- NTRB N/A
- MRNS 2014
- Fundamental
- Price
- NTRB $6.17
- MRNS $0.31
- Analyst Decision
- NTRB
- MRNS Buy
- Analyst Count
- NTRB 0
- MRNS 12
- Target Price
- NTRB N/A
- MRNS $4.56
- AVG Volume (30 Days)
- NTRB 28.2K
- MRNS 5.7M
- Earning Date
- NTRB 12-11-2024
- MRNS 11-05-2024
- Dividend Yield
- NTRB N/A
- MRNS N/A
- EPS Growth
- NTRB N/A
- MRNS N/A
- EPS
- NTRB N/A
- MRNS N/A
- Revenue
- NTRB $1,803,816.00
- MRNS $30,263,000.00
- Revenue This Year
- NTRB N/A
- MRNS $21.18
- Revenue Next Year
- NTRB N/A
- MRNS $56.42
- P/E Ratio
- NTRB N/A
- MRNS N/A
- Revenue Growth
- NTRB N/A
- MRNS 16.56
- 52 Week Low
- NTRB $1.93
- MRNS $0.26
- 52 Week High
- NTRB $9.60
- MRNS $11.26
- Technical
- Relative Strength Index (RSI)
- NTRB 50.57
- MRNS 21.75
- Support Level
- NTRB $5.24
- MRNS $0.29
- Resistance Level
- NTRB $6.40
- MRNS $1.96
- Average True Range (ATR)
- NTRB 0.71
- MRNS 0.12
- MACD
- NTRB -0.12
- MRNS -0.18
- Stochastic Oscillator
- NTRB 33.23
- MRNS 2.41
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's lead product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
About MRNS Marinus Pharmaceuticals Inc.
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.